These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 9678107

  • 21. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system.
    Spona J, Feichtinger W, Kindermann C, Schneider B, Mellinger U, Walter F, Moore C, Gräser T.
    Contraception; 1997 Aug; 56(2):67-75. PubMed ID: 9315414
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women.
    Sirtori CR, Calabresi L, Franceschini G, Gianfranceschi G, Zoppi F, Winkler S, Bilotta P, Zampetti A.
    Atherosclerosis; 1990 Oct; 84(2-3):203-11. PubMed ID: 2149269
    [Abstract] [Full Text] [Related]

  • 23. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I, Jung-Hoffmann C, Kuhl H.
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [Abstract] [Full Text] [Related]

  • 24. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters.
    Aldrighi JM, De Campos LS, Eluf Gebara OC, Petta CA, Bahamondes L.
    Gynecol Endocrinol; 2006 Jan; 22(1):1-4. PubMed ID: 16522526
    [Abstract] [Full Text] [Related]

  • 25. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Lange E, Mellinger U, Kuhl H.
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [Abstract] [Full Text] [Related]

  • 26. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel.
    Winkler UH, Daume E, Sudik R, Oberhoff C, Bier U, Hallmann C, Andreas JO, Schindler AE.
    Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):145-54. PubMed ID: 10574640
    [Abstract] [Full Text] [Related]

  • 27. Hemostasis profile in women taking low-dose oral contraceptives.
    David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):420-3. PubMed ID: 2142579
    [Abstract] [Full Text] [Related]

  • 28. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 29. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J, Müller U, Düsterberg B.
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [Abstract] [Full Text] [Related]

  • 30. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
    Daly L, Bonnar J.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
    [Abstract] [Full Text] [Related]

  • 31. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A.
    Contraception; 1994 Aug; 50(2):153-65. PubMed ID: 7956214
    [Abstract] [Full Text] [Related]

  • 32. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F, Lehnert J, Lachnit U.
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [Abstract] [Full Text] [Related]

  • 33. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.
    Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W.
    Drugs R D; 2011 Oct; 11(2):159-70. PubMed ID: 21679006
    [Abstract] [Full Text] [Related]

  • 34. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
    Fuchs N, Düsterberg B, Weber-Diehl F, Mühe B.
    Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
    [Abstract] [Full Text] [Related]

  • 35. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [Abstract] [Full Text] [Related]

  • 36. Oral contraceptives and blood coagulation.
    Bonnar J, Sabra AM.
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [Abstract] [Full Text] [Related]

  • 37. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A.
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [Abstract] [Full Text] [Related]

  • 38. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE, Berger GM, Maritz JS.
    S Afr Med J; 1991 Apr 06; 79(7):376-9. PubMed ID: 1826569
    [Abstract] [Full Text] [Related]

  • 39. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism.
    Endrikat J, Klipping C, Gerlinger C, Ruebig A, Schmidt W, Holler T, Düsterberg B.
    Contraception; 2001 Oct 06; 64(4):235-41. PubMed ID: 11747873
    [Abstract] [Full Text] [Related]

  • 40. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives.
    Briggs MH.
    J Reprod Med; 1983 Jan 06; 28(1 Suppl):92-9. PubMed ID: 6403706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.